9
High-Risk/End-stage Patient With Functional MR: Should We Treat with Anything? Steven R. DeBeer, MD Cardiothoracic Surgery Fellow Emory University AATS April 2015
| Date post: | 04-Jan-2016 |
| Category: |
Documents |
| Upload: | brandon-wells |
| View: | 212 times |
| Download: | 0 times |
Controlled Intermittent Asystole: Pharmacologic Potentiation of Vagal-Induced Asystole
DisclosuresNone
Preoperative AssessmentPulmonary Function TesteingFVC:Post BD=1.23 (50%)FEV1:Post BD=0.78 (42%)DLCO:8.4 (45%)Current Medical ManagementBeta-blockerASAStatinARBAldosterone antagonistLoop diureticInhaled steroid/beta-agonistInsulin
TEE
EF=20%Severe global hypokinesisAkinetic apexMod-severe MRCentral secondary to restricted P2 scallop mobilityCoaptation length
